Adams a1c

Manufactured by Arkray

Sourced in Japan

The ADAMS A1c is a laboratory equipment product manufactured by Arkray. It is used for the measurement of glycated hemoglobin (HbA1c) levels in blood samples. The ADAMS A1c provides accurate and reliable HbA1c test results, which are essential for monitoring and managing diabetes.

Automatically generated - may contain errors

Lab products found in correlation

Cobas 8000 analyzer, by Roche (1 mentions) Konelab analyzer, by Thermo Fisher Scientific (1 mentions) Eclusys insulin, by Roche (1 mentions) Lumipulse presto insulin, by Fujirebio (1 mentions)

3 protocols using adams a1c

Antihyperglycemic Medication Trends in Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols

We analyzed data collected on study patients in January for each year; however, when data from January were not available for a patient, data from February or March were used. The types of therapy were divided into eight categories: insulin, sulfonylureas, biguanides, alpha‐glucosidase inhibitors (α‐GI), thiazolidinediones, dipeptidyl peptidase‐4 inhibitors (DPP‐4I), glinides and glucagon‐like peptide‐1 receptor agonists (GLP‐1). For the calculation of rates of prescription of each type of medication, we calculated the number of patients prescribed each specific antihyperglycemic medication divided by the total number of patients receiving antidiabetic therapy for each year. Glycated hemoglobin (HbA1c) was measured by high‐performance liquid chromatography using either the ADAMS A1c (Arkray, Kyoto, Japan) or HLC‐723 (Tosoh Corp., Tokyo, Japan). HbA1c was converted from the Japanese Diabetes Society values into National Glycohemoglobin Standardization Program equivalent values12. Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or the current use of antihypertensive agents.

Fujihara K., Hanyu O., Heianza Y., Suzuki A., Yamada T., Yokoyama H., Tanaka S., Yagyu H., Shimano H., Kashiwagi A., Yamazaki K., Kawai K, & Sone H. (2015). Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists. Journal of Diabetes Investigation, 7(2), 260-269.

+ Open protocol

+ Expand

Biomarker Analysis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Glycohemoglobin (HbA1c) was measured with a fully automated High-Performance Liquid Chromatography system (ADAMS A1c from ARKRAY, Kyoto, Japan). Total cholesterol and HDL cholesterol, liver enzyme activities, C-reactive protein (CRP), creatinine, triglycerides, and glucose were quantified by the use of a cobas 8000 analyzer and assays from Roche diagnostics (Rotkreuz, Switzerland). LDL-cholesterol was computed with the Friedewald formula. ApoA-I and apoB were measured by immunonephelometry with the BN ProSpec analyzer and assays from Siemens Healthcare diagnostics (Erlangen, Germany). Lp(a) concentrations were measured by the application of a latex-enhanced immunoturbidimetric assay of Randox Laboratories Ltd. (Crumlin, UK) to a Konelab analyzer (Thermo Fisher, Waltham, MA, USA).

Kolb L.N., Othman A., Rohrer L., Krützfeldt J, & von Eckardstein A. (2023). Altered Distribution of Unesterified Cholesterol among Lipoprotein Subfractions of Patients with Diabetes Mellitus Type 2. Biomolecules, 13(3), 497.

+ Open protocol

+ Expand

Oral Glucose Tolerance Test Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

After the baseline blood sampling, a standard 75-g OGTT was performed [17] , and serum samples for measuring glucose and immunoreactive insulin (IRI) were obtained at 0 min, 30 min, 60 min, 90 min, and 120 min after the glucose loading. Serum IRI levels were measured using an enzyme immunoassay (LS "Eiken" Insulin; Eiken Chemical Co., Ltd., Tokyo, Japan) between January 2005 and June 2006, using a chemiluminescent immunoassay (CLEIA) (Lumipulse Presto Insulin; Fujirebio, Inc., Tokyo, Japan) between June 2006 and March 2012, and using an electro-chemiluminescent immunoassay (ECLIA) (ECLusys Insulin; Roche Diagnostics, Basel, Switzerland) between April 2012 and December 2016. The results of the OGTT were defined as normal glucose tolerance (NGT), impaired fasting glucose (IFG), IGT, or DM according to the Japan Diabetes Society guidelines [15] . Plasma glycated hemoglobin (HbA1c) levels were reported in National Glycohemoglobin Standardization Program units and were measured using high-performance liquid chromatography (ADAMS A1c; Arkray, Inc., Tokyo, Japan).

Tsurutani Y., Miyoshi K., Inoue K., Takiguchi T., Saito J., Omura M, & Nishikawa T. (2019). Changes in glucose metabolism based on 75-g oral glucose tolerance tests before and after surgery for adrenal Cushing's syndrome. Endocrine journal, 66(3).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!